Methods and materials for identifying and treating membranous nephropathy
US-2024353404-A1 · Oct 24, 2024 · US
Chemoenzymatic glycoengineering of antibodies and Fc fragments thereof
US9845360B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9845360-B2 |
| Application number | US-201615256854-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 6, 2016 |
| Priority date | Feb 10, 2012 |
| Publication date | Dec 19, 2017 |
| Grant date | Dec 19, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides for recombinant Endo-S mutants that exhibit reduced hydrolysis activity and increased transglycosylation activity for the synthesis of glycoproteins wherein a desired sialylated oxazoline or synthetic oligosaccharide oxazoline is added to a core fucosylated or nonfucosylated GlcNAc-protein acceptor. Such recombinant Endo-S mutants are useful for efficient glycosylation remodeling of IgG1-Fc domain to provide different antibody glycoforms carrying structurally well-defined Fc N-glycans.
First claim
Opening claim text (preview).
That which is claimed is: 1. A composition comprising at least one Streptococcus pyogenes Endo-S Asp-233 mutant selected from the group consisting of SEQ ID NO:2 (D233Q) and SEQ ID NO: 3 (D233A) and a tris or phosphate buffer.
Assignees
Inventors
Classifications
against material from animals or humans · CPC title
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
the antibody targeting a receptor, a cell surface antigen or a cell surface determinant · CPC title
Stability, e.g. half-life, pH, temperature or enzyme-resistance · CPC title
the tumour determinant being from a cell of a blood cancer · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9845360B2 cover?
- The present invention provides for recombinant Endo-S mutants that exhibit reduced hydrolysis activity and increased transglycosylation activity for the synthesis of glycoproteins wherein a desired sialylated oxazoline or synthetic oligosaccharide oxazoline is added to a core fucosylated or nonfucosylated GlcNAc-protein acceptor. Such recombinant Endo-S mutants are useful for efficient glycosyl…
- Who is the assignee on this patent?
- Univ Maryland
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2887. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).